Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 2012

View Archived Issues

Novel antithrombotic agents presented by Bristol-Myers Squibb

New tamsulosin prodrugs prepared by Synthon

Affectis Pharmaceuticals presents novel P2X7 receptor antagonists

Novel monoclonal antibodies patented by IRM and Novartis

Mepolizumab reduces exacerbation rates in asthma patients

Third patient successfully treated with Pluristem's PLX cells

Phase I/II ublituximab trial begins in B-cell non-Hodgkin's lymphoma

Researchers at Zyngenia disclose novel fusion proteins

Light study of Contrave experiences accelerated enrollment

Oncothyreon expands phase II trial of PX-866

Novel S1P4 receptor antagonists synthesized by Biogen Idec

ImmunoCellular Therapeutics completes enrollment in ICT-107 trial

BT-2111 shows promise in animal models of breast cancer

Adynxx's AYX-1 set to move to phase II

Targacept to develop TC-5214 in overactive bladder

Phase II results demonstrate efficacy of QMF-149 in patients with persistent asthma

ALV-003 receives FDA fast track designation for celiac disease

New lysophospholipid S1P1 receptor agonists presented at ACS meeting

Rienso receives Swiss marketing authorization

NPS Pharmaceuticals updates plans for Natpara BLA

Baxter begins phase I monoclonal antibody trial in patients with solid tumors

Acadia Pharmaceuticals completes enrollment in phase III pimavanserin trial

Study evaluates dose-response of umeclidinium in COPD

Meda to buy Jazz Pharmaceuticals' women's health business

FDA extends PDUFA date for Ravicti NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
JPM 2026: Year kicks off with biopharma Q4 revenue and guidance
BioWorld
It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...